Metabolic transformation in cancer

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1269-1280

  Tennant, Daniel A ^a   Durán, Raúl V ^a   Boulahbel, Houda ^a   Gottlieb, Eyal ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PENTOSE PHOSPHATE; PHOSPHOGLYCERATE MUTASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; TRICARBOXYLIC ACID; TUBERCULOSIS COMPLEX 2; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL HYPOXIA; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; GLYCOLYSIS; GROWTH INHIBITION; METABOLIC REGULATION; METASTASIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; UPREGULATION; ENERGY METABOLISM; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY;

ENERGY METABOLISM; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 67650165225     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp070     Document Type: Review

References (172)

1. Frezza, C. et al. (2009)Mitochondria in cancer: Not just innocent bystanders. Semin. Cancer Biol., 19, 4-11.
2. Warburg, O. (1923) Metabolism of tumours. Biochem. Z., 142, 317-333.
3. Warburg, O. (1956) On respiratory impairment in cancer cells. Science 124, 269-270.
4. Warburg, O. (1956) On the origin of cancer cells. Science, 123 309-314.
5. Pasteur, L. (1861) Expériences et vues nouvelles sur la nature des fermentations. C. R. Acad. Sci., 52, 344-347.
6. Crabtree, H. (1928) The carbohydrate metabolism of certain pathological growths. Biochem. J., 22, 1289-1298.
7. Kondoh, H. et al. (2007) A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid. Redox Signal., 9, 293-299.
8. Gatenby, R. A. et al. (2007) Glycolysis in cancer: A potential target for therapy. Int. J. Biochem. Cell Biol., 39, 1358-1366.
9. Dewhirst, M. W. (1998) Concepts of oxygen transport at the microcirculatory level. Semin. Radiat. Oncol., 8, 143-150.
10. Rofstad, E. K. et al. (2007) Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin. Cancer Res., 13 1971-1978.
11. Wang, G. L. et al. (1995) Hypoxia-inducible factor 1 is a basic-helix-loophelix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA, 92, 5510-5514.
12. Tian, H. et al. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev., 11, 72-82.
13. Maynard, M. A. et al. (2007) Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle, 6, 2810-2816.
14. Bruick, R. K. et al. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294, 1337-1340.
15. Hirsila, M. et al. (2003) Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem., 278, 30772-30780.
16. Epstein, A. C. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, 43-54.
17. Huang, J. et al. (2002) Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J. Biol. Chem., 277, 39792-39800.
18. Hewitson, K. S. et al. (2003) The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem. Soc. Trans., 31, 510-515.
19. Maxwell, P. H. et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
20. Cockman, M. E. et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 275, 25733-25741.
21. Lando, D. et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev., 16, 1466-1471.
22. McNeill, L. A. et al. (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J., 367, 571-575.
23. Lando, D. et al. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 295, 858-861.
24. Berra, E. et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J., 22, 4082-4090.
25. Appelhoff, R. J. et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem., 279, 38458-38465.
26. Ladroue, C. et al. (2008) PHD2 mutation and congenital erythrocytosis with paraganglioma. N. Engl. J. Med., 359, 2685-2692.
27. Lee, S. et al. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell, 8, 155-167.
28. Schlisio, S. et al. (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev., 22, 884-893.
29. Koditz, J. et al. (2007) Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood, 110, 3610-3617.
30. Koong, A. C. et al. (1994) Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res., 54, 1425-1430.
31. Cummins, E. P. et al. (2006) Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl Acad. Sci. USA, 103, 18154-18159.
32. Discher, D. J. et al. (1998) Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem., 273, 26087-26093.
33. Kaluz, S. et al. (2003) Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res., 63 917-922.
34. Couvelard, A. et al. (2008) Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin. Cancer Res., 14, 6634-6639.
35. Chavez, J. C. et al. (2000) Expression of hypoxia-inducible factor-1alpha in the brain of rats during chronic hypoxia. J. Appl. Physiol., 89, 1937-1942.
36. Ginouves, A. et al. (2008) PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc. Natl Acad. Sci. USA, 105, 4745-4750.
37. Dewhirst, M. W. (2007) Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res., 67, 854-855.
38. Brunelle, J. K. et al. (2005) Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab., 1, 409-414.
39. Chandel, N. S. et al. (1998) Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA, 95, 11715-11720.
40. Chandel, N. S. et al. (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing. J. Biol. Chem., 275 25130-25138.
41. Guzy, R. D. et al. (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab., 1, 401-408.
42. Mansfield, K. D. et al. (2005) Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab., 1, 393-399.
43. DeHaan, C. et al. (2004) Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Mol. Cancer, 3, 19.
44. Wang, W. et al. (2008) Superoxide flashes in single mitochondria. Cell, 134, 279-90.
45. Hagen, T. et al. (2003) Redistribution of intracellular oxygen in hypoxia by nitric oxide: Effect on HIF1alpha. Science, 302, 1975-1978.
46. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
47. Semenza, G. L. et al. (1996)Hypoxia response elements in the aldolaseA, enolase 1, and lactate dehydrogenaseA gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem., 271, 32529-32537.
48. Kim, J. W. et al. (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 3, 177-185.
49. Ullah, M. S. et al. (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem., 281, 9030-9037.
50. Shimoda, L. A. et al. (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell. Mol. Physiol., 291, L941-L949.
51. Wykoff, C. C. et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 60, 7075-7083.
52. Hunt, T. K. et al. (2007) Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid. Redox Signal., 9, 1115-1124.
53. Gatenby, R. A. et al. (2001) Mathematical models of tumour invasion mediated by transformation-induced alteration of microenvironmental pH. Novartis Found. Symp., 240, 85-96(discussion 96-99).
54. Gatenby, R. A. et al. (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: Insights through mathematical models. Cancer Res., 63, 3847-3854.
55. Fischer, K. et al. (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109, 3812-3819.
56. Liao, D. et al. (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res., 67, 563-572.
57. Maxwell, P. H. et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA, 94, 8104-8109.
58. Raval, R. R. et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol., 25, 5675-5686.
59. Ryan, H. E. et al. (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J., 17, 3005-3015.
60. Ryan, H. E. et al. (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res., 60, 4010-4015.
61. Birner, P. et al. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60, 4693-4696.
62. Schindl, M. et al. (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res., 8, 1831-1837.
63. Takahashi, R. et al. (2003) Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep., 10, 797-802.
64. Semenza, G. L. (2002) Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med., 41, 79-83.
65. Kaelin, W. G. (2007) Von Hippel-Lindau disease. Annu. Rev. Pathol. 2, 145-173.
66. Zundel, W. et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14, 391-396.
67. Flugel, D. et al. (2007) Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol. Cell. Biol., 27, 3253-3265.
68. Emerling, B. M. et al. (2008) PTEN regulates p300-dependent hypoxiainducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl Acad. Sci. USA, 105, 2622-2627.
69. Tang, T. T. et al. (2003) The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. J. Biol. Chem., 278, 30125-30135.
70. Walmsley, S. R. et al. (2005) Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J. Exp. Med. 201, 105-115.
71. Belaiba, R. S. et al. (2007) Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol. Biol. Cell, 18, 4691-4697.
72. Rius, J. et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-811.
73. Hudson, C. C. et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 22, 7004-7014.
74. Hebert, C. et al. (2006) Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol. Cancer, 5, 3.
75. Bernardi, R. et al. (2006) PML inhibits HIF-1alpha translation and neo-angiogenesis through repression of mTOR. Nature, 442, 779-785.
76. Dang, C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol., 19, 1-11.
77. Adhikary, S. et al. (2005) Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol., 6 635-645.
78. Kim, J. W. et al. (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol., 27, 7381-7393.
79. Yeung, S. J. et al. (2008) Roles of p53, Myc and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell. Mol. Life Sci., 65, 3981-3999.
80. DeBerardinis, R. J. et al. (2008) The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 7, 11-20.
81. Zhang, H. et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11, 407-420.
82. Macheda, M. L. et al. (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol., 202, 654-662.
83. Dang, C. V. et al. (1997) Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J. Bioenerg. Biomembr., 29, 345-354.
84. Gottlob, K. et al. (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev., 15, 1406-1418.
85. Majewski, N. et al. (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell, 16, 819-830.
86. Pastorino, J. G. et al. (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem., 277, 7610-7618.
87. Yanagawa, T. et al. (2004) Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocr. Relat. Cancer, 11, 749-759.
88. Maruyama, K. et al. (1995) Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int. J. Cancer 64, 316-321.
89. Nakamori, S. et al. (1994) Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer, 74, 1855-1862.
90. Niizeki, H. et al. (2002) Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br. J. Cancer, 86, 1914-1919.
91. Takanami, I. et al. (1998) Autocrine motility factor in pulmonary adenocarcinomas: Results of an immunohistochemical study. Tumour Biol., 19, 384-389.
92. Taniguchi, K. et al. (1998) The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer, 82, 2112-2122.
93. Yoon, D. Y. et al. (2001) Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys. Res. Commun., 288, 882-886.
94. Tsutsumi, S. et al. (2003) Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res., 63, 242-249.
95. Atsumi, T. et al. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res., 62, 5881-5887.
96. Minchenko, A. et al. (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J. Biol. Chem., 277, 6183-6187.
97. Almeida, A. et al. (2004) Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat. Cell Biol., 6, 45-51.
98. Kole, H. K. et al. (1991) Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Arch. Biochem. Biophys., 286, 586-590.
99. Telang, S. et al. (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene, 25, 7225-7234.
100. Bensaad, K. et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107-120.
101. Kondoh, H. et al. (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res., 65, 177-185.
102. Iyer, N. V. et al. (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev., 12 149-162.
103. Yamada, K. et al. (1999) Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem. J., 337, 1-11.
104. Christofk, H. R. et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233.
105. Eigenbrodt, E. et al. (1992) Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog., 3, 91-115.
106. Presek, P. et al. (1988) Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett., 242, 194-198.
107. Christofk, H. R. et al. (2008) Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature, 452, 181-186.
108. Eigenbrodt, E. et al. (1983) Influence of transformation by Rous sarcoma virus on the amount, phosphorylation and enzyme kinetic properties of enolase. EMBO J., 2, 1565-1570.
109. Kamps, M. P. et al. (1986) Rous sarcoma virus transforming protein lacking myristic acid phosphorylates known polypeptide substrates without inducing transformation. Cell, 45, 105-112.
110. Papandreou, I. et al. (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab., 3, 187-197.
111. Bonnet, S. et al. (2007) A mitochondria-K channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 11, 37-51.
112. Pearson, H. (2007) Cancer patients opt for unapproved drug. Nature 446, 474-475.
113. Fantin, V. R. et al. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-434.
114. Board, M. et al. (1990) Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J., 265, 503-509.
115. Hatzivassiliou, G. et al. (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8, 311-321.
116. Pizer, E. S. et al. (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res., 56, 1189-1193.
117. Deberardinis, R. J. et al. (2006) Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J. Biol. Chem., 281, 37372-37380.
118. Curi, R. et al. (2005) Molecular mechanisms of glutamine action. J. Cell. Physiol., 204, 392-401.
119. Eagle, H. (1955) Nutrition needs of mammalian cells in tissue culture. Science, 122, 501-514.
120. DeBerardinis, R. J. et al. (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA, 104, 19345-19350.
121. Crabtree, B. et al. (1985) A quantitative approach to metabolic control. Curr. Top. Cell. Regul., 25, 21-76.
122. Fischer, J. E. et al. (1990) Total parenteral nutrition, glutamine, and tumor growth. JPEN J. Parenter. Enteral. Nutr., 14, 86S-89S.
123. Souba, W. W. (1993) Glutamine and cancer. Ann. Surg., 218, 715-728.
124. Perez-Gomez, C. et al. (2005) Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem. J., 386, 535-542.
125. Chance, W. T. et al. (1988) Insulin and acivicin improve host nutrition and prevent tumor growth during total parenteral nutrition. Ann. Surg., 208, 524-531.
126. Ovejera, A. A. et al. (1979) Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxonorleucine against experimental tumors in conventional and nude mice. Cancer Res., 39, 3220-3224.
127. Gottlieb, E. et al. (2005) Mitochondrial tumour suppressors: A genetic and biochemical update. Nat. Rev. Cancer, 5, 857-866.
128. Gimenez-Roqueplo, A. P. et al. (2001) The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet., 69, 1186-1197.
129. Pollard, P. J. et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet., 14, 2231-2239.
130. Isaacs, J. S. et al. (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell, 8, 143-153.
131. Koivunen, P. et al. (2007) Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: Possible links between cell metabolism and stabilization of HIF. J. Biol. Chem., 282, 4524-4532.
132. Selak, M. A. et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85.
133. Guzy, R. D. et al. (2008) Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol. Cell. Biol., 28, 718-731.
134. Selak, M. A. et al. (2006) Redox stress is not essential for the pseudohypoxic phenotype of succinate dehydrogenase deficient cells. Biochim. Biophys. Acta, 1757, 567-572.
135. Murphy, M. P. (2009) How mitochondria produce reactive oxygen species. Biochem. J., 417, 1-13.
136. Hoffman, D. L. et al. (2007) Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: Implications for hypoxic cell signaling. Am. J. Physiol. Heart Circ. Physiol., 292, H101-H8.
137. Matoba, S. et al. (2006) p53 regulates mitochondrial respiration. Science, 312, 1650-1653.
138. Fukuda, R. et al. (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111-122.
139. Baggetto, L. G. (1992) Deviant energetic metabolism of glycolytic cancer cells. Biochimie, 74, 959-974.
140. Fuchs, B. C. et al. (2005) Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin. Cancer Biol., 15, 254-266.
141. Bode, B. P. et al. (2002) Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am. J. Physiol. Gastrointest. Liver Physiol., 283, G1062-G1073.
142. Fuchs, B. C. et al. (2004) Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol., 286, G467-G478.
143. McGivan, J. D. et al. (2007) The transport of glutamine into mammalian cells. Front. Biosci., 12, 874-882.
144. Nawashiro, H. et al. (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int. J. Cancer 119, 484-492.
145. Oshiro, N. et al. (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells, 9, 359-366.
146. Avruch, J. et al. (2006) Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene, 25, 6361-6372.
147. Kim, E. et al. (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol., 10, 935-945.
148. Sancak, Y. et al. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science, 320, 1496-1501.
149. Sarbassov, D. D. et al. (2005) Growing roles for the mTOR pathway. Curr. Opin. Cell Biol., 17, 596-603.
150. Jacinto, E. et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 6, 1122-1128.
151. Hresko, R. C. et al. (2005) mTOR. RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem., 280 40406-40416.
152. Sarbassov, D. D. et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 22, 159-168.
153. Wullschleger, S. et al. (2006) TOR signaling in growth and metabolism. Cell, 124, 471-484.
154. Long, X. et al. (2005) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem., 280, 23433-23436.
155. Fuchs, B. C. et al. (2007) ASCT2 silencing regulates mammalian target-ofrapamycin growth and survival signaling in human hepatoma cells. Am. J. Physiol. Cell Physiol., 293, C55-C63.
156. Edinger, A. L. et al. (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res., 63, 8451-8460.
157. Edinger, A. L. et al. (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell, 13, 2276-2288.
158. Li, C. et al. (2003) Regulation of leucine-stimulated insulin secretion and glutamine metabolism in isolated rat islets. J. Biol. Chem., 278, 2853-2858.
159. Li, C. et al. (2006) Effects of a GTP-insensitive mutation of glutamate dehydrogenase on insulin secretion in transgenic mice. J. Biol. Chem., 281, 15064-15072.
160. Stanley, C. A. et al. (1998) Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N. Engl. J. Med., 338, 1352-1357.
161. Meissner, T. et al. (2004) Urinary alpha-ketoglutarate is elevated in patients with hyperinsulinism-hyperammonemia syndrome. Clin. Chim. Acta, 341, 23-26.
162. Cantley, L. C. et al. (1999) New insights into tumor suppression: pTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA, 96, 4240-4245.
163. Tee, A. R. et al. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl Acad. Sci. USA, 99, 13571-13576.
164. Mavrakis, K. J. et al. (2008) Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev., 22, 2178-2188.
165. Lassman, A. B. et al. (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res., 11, 7841-7850.
166. LoPiccolo, J. et al. (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat., 11, 32-50.
167. Majumder, P. K. et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med., 10, 594-601.
168. Saal, L. H. et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA, 104, 7564-7569.
169. Thomas, G. V. et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med., 12, 122-127.
170. Guertin, D. A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
171. Um, S. H. et al. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature, 431, 200-205.
172. Abraham, R. T. et al. (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets, 12 209-222.